B-cell Lymphoma Refractory Clinical Trials

21 clinical trials for B-cell Lymphoma Refractory across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas — RECRUITING · PHASE1
• Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia — RECRUITING · PHASE2
• Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies — RECRUITING · PHASE1
• CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL — RECRUITING · PHASE1
• MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) — ACTIVE_NOT_RECRUITING · PHASE1
• Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation — ACTIVE_NOT_RECRUITING · PHASE2
• Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma — TERMINATED · PHASE2
• Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies — ACTIVE_NOT_RECRUITING · PHASE2
• Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma — TERMINATED · PHASE1
• MB-CART20.1 Lymphoma — COMPLETED · PHASE1
• Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. — TERMINATED
• Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL — TERMINATED · PHASE1
• A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma — OTHER · PHASE1
• Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma — NOT_YET_RECRUITING · PHASE1
• CAR T Cell Therapy Related Cardiovascular Outcomes — COMPLETED
• CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Induced-T Cell Like NK Cells for B Cell Malignancies — OTHER · PHASE1
• CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL — OTHER · PHASE1
• Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma — COMPLETED · PHASE1
• Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas — OTHER · PHASE2

Refine this search